Securities and Exchange Commission
                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

          Date of Report (Date of earliest event reported): May 7, 1998

                                  Biogen, Inc.
             (Exact name of Registrant as specified in its charter)


Massachusetts                 0-12042                  04-3002117
(State or other               (Commission              (IRS Employer
jurisdiction of               File Number)             Identification No.)
incorporation)


                               14 Cambridge Center
                               Cambridge, MA 02142
               (Address of principal executive offices) (Zip Code)


Registrant's telephone number, including area code: (617) 679-2000







Item 5.   Other Events.

         On May 6, 1998,  the Registrant  publicly  disseminated a press release
announcing  a decision by the U.S.  Federal  District  Court for the District of
Massachusetts   in  connection   with  a  class-action   suit  relating  to  the
Registrant's 1994 public comments about HIRULOG(R) (bivalirudin) direct thrombin
inhibitor.  The jury  rejected  all claims  made by the  plaintiffs  against the
Registrant.

         The information  contained in the press release is incorporated  herein
by reference and filed as Exhibit 99.1 hereto.

Item 7.  Financial Statements and Exhibits.

(c)  Exhibits.

        99.1         The Registrant's Press Release dated May 6, 1998.







                                   SIGNATURES

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                             Biogen, Inc.



                                             By: /s/ Michael J. Astrue
                                                 Michael J. Astrue
                                                 Vice President -General Counsel




Date: May 7, 1998








                                  EXHIBIT INDEX

Exhibit
Number                     Description

99.1                       The Registrant's Press Release
                                    dated May 6, 1998








Exhibit 99.1

Media Contact:
Kathryn R. Bloom
Director of Communications
Biogen, Inc.
tel: (617) 679-2851

Investment Community Contacts:
John Conley                                       Elizabeth Woo
Treasurer and Director, Investor Relations        Manager, Investor Relations
Biogen, Inc.                                      Biogen, Inc.
tel: (617) 679-2812                               tel: (617) 679-2822

                                          FOR IMMEDIATE RELEASE


                         BIOGEN WINS CLASS-ACTION SUIT;
               UNANIMOUS DECISION CONFIRMS CASE WAS WITHOUT MERIT


Cambridge,  MA (May 6, 1998) --  Biogen,  Inc.  (NASDAQ/BGEN)  today said it was
pleased  by a jury's  verdict in the U.S.  District  Court for the  District  of
Massachusetts  rejecting  all claims made by a class of  plaintiffs  against the
company  relating to Biogen's 1994 public  comments on HIRULOG(R)  (bivalirudin)
direct thrombin inhibitor.

Jim Vincent,  Biogen's  Chairman,  said, "This abusive lawsuit is typical of the
kind  of  suit  targeted  by  recent  Congressional   reform  legislation,   and
underscores the need for further reform in this area of our legal system such as
the legislation that is currently pending before Congress.

"As expected,  the jury  recognized  that  Biogen's  statements  were  truthful,
complete  and  timely.  In our  20-year  history,  we  had  never  before  had a
shareholder suit and we are pleased to retain our unblemished record of accuracy
and honesty.  We will now put this matter  behind us and continue our mission of
developing life-saving and life-improving drugs."

Biogen,  Inc.,  headquartered in Cambridge,  MA, is a biopharmaceutical  company
principally  engaged in discovering  and developing  drugs for human  healthcare
through genetic engineering.  The Company's revenues are generated from U.S. and
European  sales of AVONEX(R)  (Interferon  beta-1a)  for  treatment of relapsing
forms of multiple  sclerosis,  and from the  worldwide  sales by  licensees of a
number of products,  including  alpha  interferon  and  hepatitis B vaccines and
diagnostic products. Biogen's research and development activities are focused on
novel products for multiple  sclerosis,  inflammatory,  respiratory,  kidney and
cardiovascular  diseases  and in  developmental  biology and gene  therapy.  For
copies of press releases and additional  information  about the Company,  please
consult Biogen's Homepage on the World Wide Web at http://www.biogen.com.

                                                       # # #